PDUFA VII Communications: Earlier PMR Talks, Formal Meeting Additions
Executive Summary
Sponsors will receive additional agency interactions through the formal meeting process, as well as an option to ask clarifying questions later.
You may also be interested in...
Sangamo’s Fabry Gene Therapy Can Rely On 25-Person Registration Trial After US FDA Meeting
With a PRIME designation also in hand for isaralgagene civaparvovec, Sangamo still needs to secure a partner before beginning its pivotal trial, which importantly will not have to include a head-to-head comparison with enzyme replacement therapies.
Requests For In-Person Formal Meetings With US FDA Increasing, But Will They Ever Dominate Again?
FDA data suggests sponsors still seem enamored with virtual meetings, even as the FDA expands the sessions eligible for in-person attendance.
US FDA’s No Recording Meetings Rule Already Appears Flexible
At least one sponsor has been recording meetings for several years, suggesting others could receive permission, but the decision comes with risks as well as benefits. As the agency again expands options for in-person meetings, sponsors may want to reflect on what works best for them.